ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0510

A risk estimation tool for clinical practice to improve early ILD detection in Sjögren Disease

Anna-Maria Hoffmann-Vold1, Kastriot Kastrati2, Marco Sprecher3, Emily Violette Langballe1, Phuong Diep1, Havard Fretheim1, Helena Andersson1, Paul Studenic4, Bojana Müller-Durovic3, Cathrine Brunborg1, Cosimo Bruni5, Christian Clarenbach3, Thomas Frauenfelder6, Trond Mogens Aaløkken1, Natasha Moe1, Helmut Prosch4, Helga Radner2, Øyvind Molberg7 and Oliver Distler8, 1Oslo University Hospital, Oslo, Norway, 2Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 3Univeristy Hospital Zurich, Zurich, Switzerland, 4Medical University of Vienna, Vienna, Austria, 5Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 6Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Zurich, Switzerland, 7Department of Rheumatology, Oslo University Hospital, Oslo, Norway, 8Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, interstitial lung disease, risk assessment, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0506–0521) Sjögren’s Disease – Basic & Clinical Science Poster I: Etiology, Pathogenesis, Diagnosis

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) affects 10-15% of Sjögren disease (SjD) patients, leading to increased morbidity and reduced survival. The true prevalence may be higher due to underdiagnosis, partly due to the lack of effective risk factor–based screening tools compared to other connective tissue diseases. Current guidelines recommend screening at-risk SjD patients using high-resolution computed tomography (HRCT), but effective risk factor estimation tools are lacking, leaving it unclear which patients should be referred for HRCT in practice. The objective was to develop a decision support tool for estimating the risk of ILD in SjD patients, guiding HRCT referrals in clinical practice.

Methods: We included all SjD patients from three European expert rheumatology centers (Zurich, Oslo and Vienna) with available HRCT images of the chest. All HRCT images were reviewed by expert radiologists at each site for the presence of ILD. Available data included demographic, serological and laboratory data, clinical SjD manifestations, and other comorbidities. To create the decision support tool, we developed a nomogram based on a logistic regression model (with Odds ratio (OR) and 95% confident interval (CI)) to estimate patient-specific probabilities, translating multivariable relationships into a graphical tool for clinical application. Predictor variables were selected based on clinical relevance, statistical significance and the area under the ROC curve (AUC) of the final multivariable logistic model.

Results: We included 547 SjD patients with HRCT, of which 163 (29.8%) had ILD. Demographic and clinical characteristics are presented in Table 1. In multivariable regression, age (OR 1.01, 95%CI 1.01-1.07, p< 0.001), erythrocyte sedimentation rate (ESR) (OR 1.03, 95%CI 1.01-1.04, p=0.003), and complement C3 (OR 0.13, 95%CI 0.05-0.35, p< 0.001) were significantly associated with the presence of ILD, adjusted for male sex, polyneuropathy, lymphoma, hypergammaglobulinemia and anti-La/SSB antibodies. The model was deemed acceptable (AUC 0.8). Based on this multivariable model, we built a nomogram which is a practical decision support tool estimating the probability of ILD in SjD patients, informing HRCT referrals based on individual risk.An example patient who is female, 50 years old, positive for anti-La/SSB, has hypergammaglobulinemia, an ESR of 40 mm/hour, and C3 of 0.8g/L has a total score of 15.5, which corresponds to a 50% predicted risk of having ILD.

Conclusion: We developed a nomogram-based decision support tool that effectively estimates the risk of ILD in SjD patients using key predictors such as age, sex, hypergammaglobulinemia, antibodies, extrapulmonary organ manifestation, ESR and complement C3 levels. This tool aids clinicians in making informed HRCT referral decisions, addressing potential underdiagnosis in at-risk SjD patients and improving early detection and outcomes. Future validation in broader populations is necessary to confirm its clinical utility.

Supporting image 1Table 1: Baseline characteristics of patients with SjD and HRCT scans segregated by the presence of ILD

Supporting image 2Figure 1: Nomogram estimating the ILD probability in SjD patients, informing HRCT referrals based on individual risk


Disclosures: A. Hoffmann-Vold: AbbVie, 2, Avalyn, 2, Boehringer Ingelheim, 2, 5, 6, 12, Medical writing support provided by Fleishman Hillard., Bristol-Myers Squibb, 2, Calluna Pharma, 2, Genentech, 2, Janssen, 2, 5, 6, Medscape, 2, 6, Merck Sharp & Dohme, 2, 6, Novartis, 6, Pliant Therapeutics, 2, Roche, 2, 6, Werfen, 2; K. Kastrati: AbbVie/Abbott, 6, Boehringer-Ingelheim, 6, Eli Lilly, 6, Novartis, 6; M. Sprecher: Abbvie, 5; E. Langballe: Boehringer-Ingelheim, 6; P. Diep: Boehringer-Ingelheim, 6, NordicInfu Care AB, 1; H. Fretheim: Boehringer-Ingelheim, 6; H. Andersson: None; P. Studenic: AbbVie, 6; B. Müller-Durovic: None; C. Brunborg: None; C. Bruni: Boehringer Ingelheim, 2, EMDO Foundation, 5, Iten-Kohaut Foundation, 5, Scleroderma Clinical Trials Consortium (SCTC), 5, Scleroderma Research Foundation (SRF), 2; C. Clarenbach: Boehringer-Ingelheim, 6, Roche, 6; T. Frauenfelder: AstraZeneca, 2, Bayer, 6, Siemens, 6; T. Aaløkken: None; N. Moe: Boehringer-Ingelheim, 6; H. Prosch: AstraZeneca, BMS, Boehringer Ingelheim, Bracco, Daiichi Sankyo, Janssen, MSD, Novartis, Roche, Sanofi, Siemens Healthineers, Takeda, 6, Boehringer Ingelheim, AstraZeneca, Siemens Healthineers and the Christian Doppler Research Association, EU Commission (EU4Health, Horizon Europe Healt, 5; H. Radner: None; Ø. Molberg: None; O. Distler: 4P-Pharma, 2, 6, AbbVie/Abbott, 2, 6, Acceleron, 2, 6, Acepodia Biotech, 2, 6, Aera, 2, 6, AnaMar, 2, 6, Anaveon AG, 2, 6, Argenx, 2, 6, AstraZeneca, 2, 6, BMS, 2, 5, 6, Calluna (Arxx), 2, 6, Cantargia AB, 2, 6, CITUS AG, 8, CSL Behring, 2, 6, EMD Serono, 2, 6, Galapagos, 2, 6, Galderma, 2, 6, Gossamer, 2, 6, Hemetron, 2, 5, 6, Innovaderm, 2, 5, 6, Janssen, 2, 6, Mediar, 2, 5, 6, mir-29 for the treatment of systemic sclerosis, 10, Mitsubishi Tanabe, 2, 5, 6, MSD Merck, 2, 6, Nkarta Inc., 2, 6, Novartis, 2, 6, Orion, 2, 6, Pilan, 2, 6, Prometheus, 2, 6, Quell, 2, 6, Sumitomo, 2, 5, 6, Topadur, 2, 5, 6, UCB, 2, 5, 6.

To cite this abstract in AMA style:

Hoffmann-Vold A, Kastrati K, Sprecher M, Langballe E, Diep P, Fretheim H, Andersson H, Studenic P, Müller-Durovic B, Brunborg C, Bruni C, Clarenbach C, Frauenfelder T, Aaløkken T, Moe N, Prosch H, Radner H, Molberg Ø, Distler O. A risk estimation tool for clinical practice to improve early ILD detection in Sjögren Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/a-risk-estimation-tool-for-clinical-practice-to-improve-early-ild-detection-in-sjogren-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-risk-estimation-tool-for-clinical-practice-to-improve-early-ild-detection-in-sjogren-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology